Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 11:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 62 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Excess Weight Clear all
Recruiting Phase 3 Interventional

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

NCT07745504
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Cagrilintide, Placebo cagrilintide, Placebo semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
11
States / cities
Conyers, Georgia • Honolulu, Hawaii • Oak Park, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 25, 2026, 11:51 PM EDT
Completed Phase 3 Interventional Results available

A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight

NCT05649137
View directory record Official record
Conditions
Obesity, Diabetes Mellitus, Type 2
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
23
States / cities
Birmingham, Alabama • Montgomery, Alabama • Concord, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 25, 2026, 11:51 PM EDT
Completed Not applicable Interventional

Interventions to Reduce Excess Weight Gain in Pregnancy

NCT01643356
View directory record Official record
Conditions
Overweight and Obesity, Pregnancy
Interventions
Intervention to reduce excess weight gain during pregnancy
Behavioral
Lead sponsor
Tufts University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2016 · Synced Oct 25, 2026, 11:51 PM EDT
Recruiting Phase 3 Interventional

AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

NCT07571005
View directory record Official record
Conditions
Obesity, Overweight, Obstructive Sleep Apnoea
Interventions
NNC0487-0111, Placebo (matched to NNC0487-0111)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
17
States / cities
San Diego, California • Miami, Florida • Naples, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 25, 2026, 11:51 PM EDT
Terminated Not applicable Interventional Results available

Surgical Intervention in Bariatric Patients: Excess Weight Loss in the Morbidly Obese Following Gastric Plication

NCT01077193
View directory record Official record
Conditions
Morbid Obesity
Interventions
Gastric Plication
Procedure
Lead sponsor
Ethicon Endo-Surgery
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Cleveland, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 7, 2014 · Synced Oct 25, 2026, 11:51 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)

NCT05874635
View directory record Official record
Conditions
Weight Loss, Metabolic Syndrome, Diabetes Mellitus, Type 2, Central Obesity, Insulin Resistance, Glucose Intolerance, Metabolic Glucose Disorders
Interventions
Continuous Glucose Monitor Device
Device
Lead sponsor
Signos Inc
Industry
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 25, 2026, 11:51 PM EDT
Completed Not applicable Interventional

Mood and Excess Weight Gain in Adolescent Pregnancy

NCT03086161
View directory record Official record
Conditions
Obesity, Adolescent Development, Pregnancy Related, Insulin Sensitivity, Interpersonal Relations, Stress
Interventions
Interpersonal Psychotherapy, Treatment-as-usual
Behavioral
Lead sponsor
Colorado State University
Other
Eligibility
3 Months to 19 Years · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 25, 2026, 11:51 PM EDT
Active, not recruiting Not applicable Interventional

Evaluation of Bariatric Endoscopic Antral Myotomy (BEAM) as a Treatment for Obesity

NCT05713071
View directory record Official record
Conditions
Obesity, Weight Loss, Delayed Gastric Emptying Following Procedure, Obesity, Mild, Obesity, Morbid, Obesity; Excess Calories
Interventions
Bariatric Endoscopic Antral Myotomy
Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 25, 2026, 11:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Visualizing Vascular Mechanisms of Salt Sensitivity

NCT03696433
View directory record Official record
Conditions
Obesity, Cardiovascular Risk Factor, Salt; Excess
Interventions
Low-salt diet, High-salt diet
Dietary Supplement
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 25, 2026, 11:51 PM EDT
Recruiting Not applicable Interventional

IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion

NCT07361874
View directory record Official record
Conditions
Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's, Mild Autonomous Cortisol Excess
Interventions
Intervention 1: Adrenalectomy, Intervention 2: Semaglutide
Procedure · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 25, 2026, 11:51 PM EDT
Recruiting Phase 3 Interventional

AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

NCT07339423
View directory record Official record
Conditions
Obesity
Interventions
NNC0487-0111, Placebo (matched to NNC0487-0111)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
22
States / cities
Miramar, Florida • Orlando, Florida • Conyers, Georgia + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 25, 2026, 11:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Timing of Sodium Intake and Nocturnal Sodium Excretion and Blood Pressure in Obese African Americans

NCT04021355
View directory record Official record
Conditions
Obesity, Hypertension, Circadian Dysregulation, Salt; Excess
Interventions
Oral sodium supplementation
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
25 Years to 45 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 25, 2026, 11:51 PM EDT
Recruiting Phase 3 Interventional

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

NCT07481630
View directory record Official record
Conditions
Obesity, Knee Osteoarthritis (OA)
Interventions
NNC0487-0111, Placebo (matched to NNC0487-0111 )
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
19
States / cities
Phoenix, Arizona • Walnut Creek, California • Hamden, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 25, 2026, 11:51 PM EDT
Completed Not applicable Interventional

Effects of Yerba Mate Supplementation on Metabolic Health, Physical Function, and Cognition in Older Adults With Excess Adiposity

NCT07883031
View directory record Official record
Conditions
Overweight (BMI > 25), Obesity & Overweight
Interventions
Yerba Mate, Placebo
Dietary Supplement
Lead sponsor
University of North Alabama
Other
Eligibility
60 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Florence, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 25, 2026, 11:51 PM EDT
Terminated Phase 2 Interventional Results available

Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism

NCT02001051
View directory record Official record
Conditions
Subclinical Hypercortisolism, Cushing Syndrome, Adrenal Neoplasm
Interventions
Adrenalectomy, Observation
Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 25, 2026, 11:51 PM EDT
Recruiting Phase 3 Interventional

Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

NCT07770841
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
16
States / cities
Birmingham, Alabama • Escondido, California • Huntington Park, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 25, 2026, 11:51 PM EDT
Completed Phase 2 Interventional

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight

NCT06326060
View directory record Official record
Conditions
Obesity
Interventions
NNC0519-0130, Placebo, Tirzepatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
49
States / cities
Mesa, Arizona • Little Rock, Arkansas • Searcy, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 25, 2026, 11:51 PM EDT
Recruiting Phase 3 Interventional

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

NCT07720271
View directory record Official record
Conditions
Overweight, Obesity
Interventions
zenagamtide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
41
States / cities
Anniston, Alabama • Birmingham, Alabama • Montgomery, Alabama + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 11:51 PM EDT
Active, not recruiting Phase 3 Interventional

AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

NCT07503210
View directory record Official record
Conditions
Obesity
Interventions
NNC0487-0111, Placebo (matched to NNC0487-0111)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
13
States / cities
Anniston, Alabama • Walnut Creek, California • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 25, 2026, 11:51 PM EDT
Not listed Not applicable Interventional

Evaluation of Intra-Abdominal Fat Extraction Using HydraSolve T2D™ in Obese Subjects With Type 2 Diabetes

NCT03953963
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Insulin Resistance
Interventions
HydraSolve T2D™
Device
Lead sponsor
Medality Medical
Industry
Eligibility
22 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 25, 2026, 11:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Genetic Predisposition to Food Cue Reactivity in Children

NCT03766191
View directory record Official record
Conditions
Childhood Obesity
Interventions
Food Ads, Non-food Ads
Behavioral · Other
Lead sponsor
Trustees of Dartmouth College
Other
Eligibility
8 Years to 12 Years
Enrollment
189 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 25, 2026, 11:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Use of Radiofrequency Ablation for RGB Salvage

NCT01910688
View directory record Official record
Conditions
Obesity
Interventions
RFA treatment
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Lebanon, New Hampshire • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2016 · Synced Oct 25, 2026, 11:51 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Abriendo Caminos 2: Clearing the Path to Hispanic Health

NCT03505658
View directory record Official record
Conditions
Obesity, Childhood Obesity, Nutrient; Excess, Community Health Education
Interventions
Education and Behavior
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
6 Years to 18 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
4
States / cities
Fresno, California • Urbana, Illinois • Ames, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 25, 2026, 11:51 PM EDT
Withdrawn Phase 3 Interventional

A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight

NCT07357766
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Cagrisema, Placebo CagriSema
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
26
States / cities
Birmingham, Alabama • Pelham, Alabama • Hawthorne, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 25, 2026, 11:51 PM EDT